Atlantic Management Resources (Claire Ellen Products) had CGMP violations and distributed unlisted Neuroquell Plus Cream.
What happened
FDA inspected the Westborough, MA drug manufacturing facility from July 26 to August 10, 2022. Investigators found no adequate quality unit or written quality procedures, no monitoring of storage conditions, and no batch production records. FDA also found Neuroquell Plus Cream was distributed under the firm’s name but was not listed with FDA.
What FDA found
The firm lacked an adequate quality unit and written quality procedures to oversee drug manufacturing.
21 CFR 211.22(a) and (d)It did not store drug products under appropriate temperature, humidity, and light conditions, including for a heat-, sunlight-, and moisture-sensitive bulk drug.
21 CFR 211.142(b)It had no batch production and control records or batch numbers documenting each manufacturing step.
21 CFR 211.188(b)Neuroquell Plus Cream was distributed under the firm’s own name and label but was not listed with FDA.
FD&C Act section 510(j)(1); 21 CFR 207.41; 21 CFR 207.49(a)(5)
What FDA wants
FDA asks the firm to respond in writing within 15 working days, identify what it has done to correct violations and prevent recurrence, and confirm whether it intends to resume drug manufacturing. If it resumes, FDA says it must notify the office first, resolve all deficiencies, and engage a qualified consultant to perform a six-system CGMP audit.
Who should pay attention
- companies that distribute drugs under their own label
- brands using contract manufacturers or suppliers
- retailers or pharmacies selling homeopathic drug products
This is a summary. Read the original letter on fda.gov.